Institute of Biomedical Research (OTC: MRES), DBA M2Bio Sciences, has appointed a new member to its advisory board. A distinguished leader and financial and data analytics expert, Adrian Maizey brings a rich background to his new board member role. Maizey has worked with top-tier companies around the world in an array of industries, from the private-equity and hedge-fund spaces to private consumer-retail entities. Currently the CEO of Rand Capital Coffee, the exclusive licensee for Starbucks in Southern Africa, Maizey has also served in leadership positions, including as partner and chief financial, chief operating and chief compliance officer roles, in a number of prestigious financial and investment firms. The Institute of Biomedical Research is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence as well as evidence-based sustainable products and solutions, is sharing an update. “We are thrilled to have Adrian Maizey on board with us,” said M2Bio Sciences CEO Jeff Robinson in the press release. “His extensive experience in the financial and investment sectors, coupled with his outstanding leadership at Starbucks SA, make him an invaluable addition to our advisory board. Adrian’s insights and strategic acumen will undoubtedly play a pivotal role in propelling M2Bio Sciences to new heights. We look forward to working closely with him as we strive to revolutionize the biotechnology landscape.”
To view the full press release, visit https://ibn.fm/se0FM
About the Institute of Biomedical Research Corp.
Institute of Biomedical Research, DBA M2Bio Sciences, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence (“AI”) as well as evidence-based sustainable products and solutions. The company develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx(TM), Medspresso(TM) and Liviana(TM) brands as well as AI-powered nutrition products and solutions under the M2Biome brand. In addition, the company’s research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. The company’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence. For more information about the company, please visit www.M2Bio.co.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork